Toward metrological traceability in the determination of prostate-specific antigen (PSA): Calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 5, 2008, Pages 623-629

  Stephan, Carsten ^a   Kahrs, Anna Maria ^a   Klotzek, Silke ^a   Reiche, Janett ^a   Müller, Christian ^a   Lein, Michael ^a,b   Deger, Serdar ^a   Miller, Kurt ^a   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

Method comparison; Metrological traceability; Prostate cancer; Prostate specific antigen (PSA); WHO PSA standards

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALIBRATION; CLINICAL PRACTICE; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STANDARD; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CALIBRATION; CHEMISTRY, CLINICAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 44349125832     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.129     Document Type: Article

References (34)

1. Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FH. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology 1996;48:23-32.
2. Nixon RG, Meyer GE, Blase AB, Gold MH, Brawer MK. Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol 1998;160:420-5.
3. Leewansangtong S, Goktas S, Lepoff R, Holthaus K, Crawford ED. Comparability of serum prostate-specific antigen measurement between the Hybritech Tandem-R and Abbott AxSYM assays. Urology 1998;52:467-9.
4. Patel D, White PA, Milford WA. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 2000;85:686-9.
5. Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000;86:590-7.
6. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001;88:545-50.
7. Link RE, Shariat SF, Nguyen CV, Farr A, Weinberg AD, Morton RA, et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004;171:2234-8.
8. Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52:59-64.
9. Kort SA, Martens F, Vanpoucke H, Van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006;52:1568-74.
10. Stamey TA. Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology 1995;45:173-84.
11. Stenman UH, Leinonen J, Zhang WM. Standardization of PSA determinations. Scand J Clin Lab Invest Suppl 1995;221:45-51.
12. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines DR. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 2000;46:1310-7.
13. Sturgeon CM, Ellis AR. Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems. Clin Chim Acta 2007;381:85-92.
14. Chan DW, Sokoll LJ. WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies? Clin Chem 2000;46:1291-2.
15. Sotelo RJ, Mora KE, Perez LH, Novoa J, Carmona O, De AR, et al. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen. Urology 2007;69:1143-6.
16. Clinical and Laboratory Standards Institute. Metrological traceability and its implementation; a report. CLSI document X5-R. Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2006:1-43.
17. Panteghini M. Traceability, reference systems and result comparability. Clin Biochem Rev 2007;28:97-104.
18. Oesterling JE, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. J Am Med Assoc 1993;270:860-4.
19. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2037-42.
20. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem 1983;21:709-20.
21. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60.
22. Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 1995;55(Suppl 222):43-60.
23. Laffin RJ, Chan DW, Tanasijevic MJ, Fischer GA, Markus W, Miller J, et al. Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance. Clin Chem 2001;47:129-32.
24. Blijenberg BG, Lilja H, Neels H, Stenman UH. Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee. BJU Int 2003;92(Suppl 2):66-70.
25. Roddam AW, Rimmer J, Nickerson C, Ward AM. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006;43:35-48.
26. Dittadi R, Franceschini R, Fortunato A, Zancan M, Barichello M, Tasca A, et al. Interchangeability and diagnostic accuracy of two assays for total and free prostate-specific antigen: two not always related items. Int J Biol Markers 2007;22:154-8.
27. Stamey TA, Teplow DB, Graves HC. Identity of PSA purified from seminal fluid by different methods: comparison by amino acid analysis and assigned extinction coefficients. Prostate 1995;27:198-203.
28. Belanger A, Vanhalbeek H, Graves HC, Grandbois K, Stamey TA, Huang LH, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995;27:187-97.
29. Graves HC, Kamarei M, Stamey TA. Identity of prostate specific antigen and the semen protein P30 purified by a rapid chromatography technique. J Urol 1990;144:1510-5.
30. Stephan C, Semjonow A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples - a response to AW Roddam et al., Ann Clin Biochem 2006;43:35-48. Ann Clin Biochem 2006;43:421-2.
31. Schreiber WE, Endres DB, McDowell GA, Palomaki GE, Elin RJ, Klee GG, et al. Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists surveys: alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen. Arch Pathol Lab Med 2005;129:331-7.
32. Roddam AW, Price CP, Allen NE, Ward AM. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 2004;50:1012-6.
33. Stephan C, Kramer J, Meyer HA, Kristiansen G, Ziemer S, Deger S, et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007;99:1427-31.
34. Scaramuzzino DA, Schulte K, Mack BN, Soriano TF, Fritsche HA. Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70°C or less. Int J Biol Markers 2007;22:206-13.